NCT03330990View on ClinicalTrials.gov

Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 14, 2017

Primary Completion Date

July 11, 2018

Study Completion Date

July 11, 2018

Conditions
Advanced Solid Tumor
Interventions
DRUG

Entrectinib

600 mg oral capsule (fasted and fed)

DRUG

Midazolam Hydrochloride

2 mg oral syrup (fasted)

Trial Locations (3)

34232

Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota

37203

Tennessee Oncology, Nashville

80218

SCRI-Denver Drug Development Program, Denver

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03330990 - Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients | Biotech Hunter | Biotech Hunter